882 results on '"Schulze-Koops, Hendrik"'
Search Results
2. The Uncoupling of Disease Activity from Joint Structural Progression in Patients with Rheumatoid Arthritis Treated with Filgotinib
3. FAPI PET for monitoring of rheumatological treatment in multifocal peritoneal nodular fibrosis: a case study
4. Gelenkschmerz: Wie erkenne ich eine rheumatische Ursache?
5. Colitis induced by IL-17A-inhibitors
6. Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study
7. Fachspezifische Beurteilung des Berichts der Deutschen Gesellschaft für Innere Medizin (DGIM) zur Darstellung der Versorgungslandschaft im Bereich der Inneren Medizin in Deutschland durch die Deutsche Gesellschaft für Rheumatologie e.V. (DGRh)
8. Application of blinatumomab, a bispecific anti-CD3/CD19 T-cell engager, in treating severe systemic sclerosis: A case study
9. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry
10. Rheumatologische Nebenwirkungen von Checkpointinhibitoren und deren Behandlung
11. The efficacy and safety of systemic corticosteroids as first line treatment for granulomatous lymphocytic interstitial lung disease
12. Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial
13. Impact of Risk Factors on COVID‐19 Outcomes in Unvaccinated People With Rheumatic Diseases: A Comparative Analysis of Pandemic Epochs Using the COVID‐19 Global Rheumatology Alliance Registry
14. sCD25 as an independent adverse prognostic factor in adult patients with HLH: results of a multicenter retrospective study
15. Frühe rheumatoide Arthritis
16. Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study
17. Radiographic Progression in Patients with Rheumatoid Arthritis in Clinical Remission or Low Disease Activity: Results from a Swiss National Registry (SCQM).
18. Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel)
19. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial
20. Benralizumab Reduces Respiratory Exacerbations and Oral Glucocorticosteroid Dose in Patients with Severe Asthma and Eosinophilic Granulomatosis with Polyangiitis
21. Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in the context of the SARS-CoV-2/COVID-19 pandemic, including recommendations for COVID-19 vaccination
22. Immune checkpoint inhibitor–associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation
23. Initial presenting manifestations in 16,486 patients with inborn errors of immunity include infections and noninfectious manifestations
24. Biobetters in patients with immune-mediated inflammatory disorders: An international Delphi consensus
25. Deutsches Register www.Covid19-Rheuma.de: Statusbericht nach 1 Jahr der Pandemie
26. COVID-19 vaccination in individuals with inflammatory rheumatic diseases
27. Aktualisierte Handlungsempfehlungen der Deutschen Gesellschaft für Rheumatologie für die Betreuung von Patienten mit entzündlich-rheumatischen Erkrankungen im Rahmen der SARS-CoV‑2/COVID‑19-Pandemie einschließlich Empfehlungen zur COVID‑19-Impfung
28. Dysregulated immunity in PID patients with low GARP expression on Tregs due to mutations in LRRC32
29. Methotrexate does not increase the risk of liver fibrosis in patients with rheumatoid arthritis: assessment by ultrasound elastography (ARFI-MetRA study)
30. Deutscher Rheumatologiekongress virtuell – erfolgreich tagen trotz Pandemie
31. Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long-term extension study.
32. Does the Change of Weather Influence Disease Activity in Rheumatoid Arthritis Patients: Patients' Self-Assessment via WebApp.
33. Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial
34. The protective effect of tumor necrosis factor-alpha inhibitors in COVID-19 in patients with inflammatory rheumatic diseases compared to the general population—A comparison of two German registries
35. Aktueller Stand der Impfung gegen SARS-CoV-2
36. Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study
37. The Joint Vasculitis Registry in German-speaking countries (GeVas) – a prospective, multicenter registry for the follow-up of long-term outcomes in vasculitis
38. Deutsche Forschergruppen beim Einsatz innovativer Therapien des systemischen Lupus erythematodes weit vorne
39. Colitis induced by IL-17A-inhibitors
40. Kardinalsymptome entzündlich-rheumatischer Erkrankungen
41. 3D black-blood 3T-MRI for the diagnosis of abdominal large vessel vasculitis
42. Hat Ihr Patient einen Morbus Bechterew?
43. Pathogenetic Concepts of Joint Diseases
44. Nachruf der Deutschen Gesellschaft für Rheumatologie auf Prof. Joachim R. Kalden
45. Impact of Risk Factors on COVID‐19 Outcomes in Unvaccinated People with Rheumatic Diseases
46. Spontaneous abortion as differential diagnosis of intermittent glomerular proteinuria in inactive systemic lupus erythematosus
47. Management of a patient with common variable immunodeficiency and hepatopathy
48. Methylation of an intragenic alternative promoter regulates transcription of GARP
49. Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study
50. Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions:an update
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.